← All Posts
ACA
Acadia Pharmaceuticals Inc.
May 30, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1 |
To elect the Board’s three nominees for Class I director named herein to hold office until the Company’s 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. |
✓ For(61.621)
|
| 2 |
To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. |
✓ For(61.621)
|
| 3 |
To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. |
✓ For(61.621)
|
| 4 |
To approve an amendment to the Company’s 2024 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 5,209,670 shares. |
✓ For(61.621)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial